Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus (RSV)

Latest Posts

  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Flu, RSV linked to higher odds of secondary bacterial infection​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Study details economic impact of RSV infections in young children​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Studies estimate 75% RSV vaccine efficacy in older adults, profile risk for poor outcomes​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Hospital admissions of respiratory infections in infants plunge with nirsevimab RSV antibody​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
RSV studies identify risk factors in older adults, household transmission routes​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Study shows nirsevimab provides significant protection against RSV​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Nirsevimab estimated at 64% to 74% effective against poor RSV outcomes in infants​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Reports describe good maternal RSV vaccine, drug uptake in their first season​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
UK study finds 2% of primary care antibiotic prescriptions were for RSV—a viral illness​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
RSV vaccine prompts robust immune response in older recipients over 2 seasons​
Load More
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Flu, RSV linked to higher odds of secondary bacterial infection​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Study details economic impact of RSV infections in young children​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Studies estimate 75% RSV vaccine efficacy in older adults, profile risk for poor outcomes​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Hospital admissions of respiratory infections in infants plunge with nirsevimab RSV antibody​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
RSV studies identify risk factors in older adults, household transmission routes​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Study shows nirsevimab provides significant protection against RSV​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Nirsevimab estimated at 64% to 74% effective against poor RSV outcomes in infants​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
Reports describe good maternal RSV vaccine, drug uptake in their first season​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
UK study finds 2% of primary care antibiotic prescriptions were for RSV—a viral illness​
  • Cidrap EDU, Respiratory Syncytial Virus (RSV), RSS
RSV vaccine prompts robust immune response in older recipients over 2 seasons​

One Health,
One Society:
Bridging Disciplines
for a Healthier World

MENU

NEWSLETTER

Subscribe to our newsletter and stay up to date with all events coming straight in your mailbox:

FOLLOW US

Facebook X-twitter Instagram Linkedin
Copyright © 2025 BioUnison LLC, All Rights Reserved.
One Health Society: A BioUnison Initiative
Privacy Policy | Terms of use